Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

Characterization of New Drug’s Safety Profile Before Marketing

Friedman MA et al. JAMA 1999; 281(18):1728–1734

 

  • Most drugs approved by FDA with average of 1500 patient exposures
  • Some drugs have rare toxicity profiles (bromfenac hepatotoxicity 1 in 20,000 patients)
  • For drugs with rare toxicity, more than 100,000 patients must be exposed to generate a signal i.e. after drug is marketed

 

Back to Learning Module

-
-